Search our Current Studies

Still have some questions about the process? Review our Frequently Asked Questions for the answers.
Learn More
Image

Safety and Efficacy of the Omnipod 5 Automated Insulin Delivery System in Adults With Type 2 Diabetes

Location(s): Canton, Jacksonville - Southside, Macon

Condition: Diabetes

Placebo Controlled, Double Blind, Randomized Cardiovascular Outcome Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With ASCVD Not Adequately Controlled Despite Maximally Tolerated Lipid Modifying Therapies

Location(s): Canton, Jacksonville (Headquarters), Jacksonville - LaVilla (Downtown), Jacksonville - Southside, Lake City, St. Augustine

Condition: Heart Disease, High Cholesterol

Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk

Location(s): Jacksonville (Headquarters), Jacksonville - Southside, Lake City, Macon, St. Augustine

Condition: Heart Disease, High Cholesterol

A Parallel-group Treatment, Phase 2, Double-blind, Three-arm Study to Assess Efficacy and Safety of Finerenone Plus Empagliflozin Compared With Either Finerenone or Empagliflozin in Participants With Chronic Kidney Disease and Type 2 Diabetes

Location(s): Canton, Jacksonville (Headquarters), Jacksonville - LaVilla (Downtown), Jacksonville - Southside, Lake City, Macon

Condition: Diabetes, Kidney Disease

A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)

Location(s): Macon

Condition: Overweight/Obesity

This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult participants with obesity or overweight and type 2 diabetes. The study will last about 77 weeks and may include up to 22 visits.

Location(s): Jacksonville (Headquarters)

Condition: Diabetes, Overweight/Obesity

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a).

Location(s): Jacksonville (Headquarters), Jacksonville - LaVilla (Downtown), St. Augustine

Condition: Heart Disease

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

Location(s): St. Augustine

Condition: Atrial Fibrillation, Heart Disease

IMPACT2: In-Home Study with MiniMed™ 780G Pump Automated Control in Type 2 – Evaluation of the AHCL System in Adults with Insulin-requiring Type 2 Diabetes

Location(s): Canton, Jacksonville - LaVilla (Downtown), Macon

Condition: Diabetes

A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT)

Location(s): Canton, Jacksonville (Headquarters), Jacksonville - LaVilla (Downtown), Lake City, Macon, Southside, St. Augustine

Condition: Heart Disease

A Prospective Single-Arm Multicenter StuDy of the BarE TEmporary SPur StEnt System foR the tREatment of Vascular Lesions Located in the infrapoplitEal Arteries beLow the Knee (DEEPER REVEAL)

Location(s): St. Augustine

Condition: Heart Disease

A Non-Interventional Study to Evaluate the Effect of Intraocular Lens (IOL) Centration and Tilt on Visual Performance in Patients Who Have Undergone Clareon® Vivity® IOL Implantation

Location(s): Jacksonville - Florida Eye Specialist (Gate)

Condition: Cataract, Eye Disease

Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Participants With Established Atherosclerotic Cardiovascular Disease, Chronic Kidney Disease and Systemic Inflammation

Location(s): Jacksonville (Headquarters)

Condition: Heart Disease, Kidney Disease

A Phase 3, Open-Label Study of Once Daily LY3502970 Compared With Insulin Glargine in Adult Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Location(s): Macon

Condition: Diabetes, Overweight/Obesity

Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients

Location(s): Jacksonville - Florida Eye Specialist (Gate)

Condition: Ocular Hypertension, Open-Angle Glaucoma

A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction

Location(s): Jacksonville (Headquarters), St. Augustine

Condition: Heart Failure

A Phase 3, Randomized, Multi-Regional, Double-Masked, Parallel-Group Trial Evaluating the Safety and Efficacy of NCX 470 0.1% vs. Latanoprost 0.005% in Subjects With Open-Angle Glaucoma or Ocular Hypertension (Denali)

Location(s): Jacksonville - Florida Eye Specialist (Gate)

Condition: Eye Disease, Ocular Hypertension, Open-Angle Glaucoma